Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Alistar, Sabina S ^a   Owens, Douglas K ^b,c   Brandeau, Margaret L ^a  

^a Stanford University   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; METHADONE;

ARTICLE; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; EPIDEMIC; HEALTH CARE ACCESS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; METHADONE TREATMENT; MONOTHERAPY; QUALITY ADJUSTED LIFE YEAR; UKRAINE; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; HIV INFECTIONS; HUMAN; ORAL DRUG ADMINISTRATION; PRE-EXPOSURE PROPHYLAXIS; PREVALENCE; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; PRE-EXPOSURE PROPHYLAXIS; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; UKRAINE;

EID: 84900330910     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086584     Document Type: Article

References (62)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2012) UNAIDS Report on the Global AIDS Epidemic 2012. Geneva, Switzerland: World Health Organization.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
3. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399-410.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423-434.
5. Marrazzo J, Ramjee G, Nair G, et al. (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003) [Abstract]. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA.
6. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367: 411-422.
7. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, et al. (2013) Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand: a randomized, double-blind, placebo-controlled trial. Lancet 381: 2083-2090.
8. Centers for Disease Control and Prevention (CDC) (2013) Interim guidance for preexposure prophylaxis for the prevention of HIV infection: PrEP for injecting drug users. MMWR Morb Mortal Wkly Rep 62: 463-465.
9. Alistar SS, Owens DK, Brandeau ML (2011) Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: A modeling analysis for Ukraine. PLoS Med 8: e1000423.
10. Zaric GS, Barnett PG, Brandeau ML (2000) HIV transmission and the cost-effectiveness of methadone maintenance. Am J Public Health 90: 1100-1111. (Pubitemid 30445365)
11. Zaric GS, Brandeau ML, Barnett PG (2000) Methadone maintenance and HIV prevention: a cost-effectiveness analysis. Manage Sci 46: 1013-1031.
12. MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, et al. (29012) Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 345: e5945.
13. World Health Organization (2013) Data on the HIV/AIDS response: Antiretroviral therapy coverage by country. Geneva, Switzerland.
14. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2008) Ukraine - National report on monitoring progress towards the UNGASS declaration of commitment on HIV/AIDS. Geneva: United Nations.
15. Ministry of Health of Ukraine (2012) Ukraine Harmonized AIDS Response Progress Report. Kyev, Ukraine: Ministry of Health Ukraine.
16. Kruglov YV, Kobyshcha YV, Salyuk T, Varetska O, Shakarishvili A, et al. (2008) The most severe HIV epidemic in Europe: Ukraine's national HIV prevalence estimates for 2007. Sex Transm Infect 84: i37-i41.
17. Celentano DD, Beyrer C, Wolfe D, Elovich R, Boltaev A, et al. (2008) HIV in Central Asia: Tajikistan, Uzbekistan and Kyrgyzstan. Public Health Aspects of HIV/AIDS in Low and Middle Income Countries. Springer New York. 557-581.
18. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, et al. (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 372: 1733-1745.
19. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2008) Ukraine - Country situation fact sheet. Geneva: United Nations.
20. Grönbladh L, Gunne LM (1989) Methadone-assisted rehabilitation of Swedish heroin addicts. Drug and Alcohol Dependence 24: 31-37. (Pubitemid 19167726)
21. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, et al. (2006) Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 20: 2207-2215. (Pubitemid 44684712)
22. Vickerman P, Kumaranayake L, Balakireva O, Guinness L, Artyukh O, et al. (2006) The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis 33: S89-S102. (Pubitemid 44454722)
23. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, et al. (2005) Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med 352: 570-585. (Pubitemid 40204670)
24. Panel on Antiretroviral Guidelines for Adults and Adolescents (2008) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: United States Department of Health and Human Services.
25. World Health Organization (WHO) (2006) Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach - 2006 Revision. Geneva: World Health Organization.
26. World Health Organization (2013) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization, HIV/AIDS Programme.
27. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129. (Pubitemid 34786200)
28. Grabar S, Moing VL, Goujard C, Leport C, Kazatchkine MD, et al. (2000) Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 133: 401-410.
29. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, et al. (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4 + cell count is 0.200 to 0.350×109 cells/L. Ann Intern Med 139: 810-816.
30. Castilla J, del Romero J, Hernando V, Marincovich B, Garcia S, et al. (2005) Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J AIDS 40: 96-101. (Pubitemid 41233212)
31. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
32. World Health Organization (WHO) (2003) Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization.
33. World Health Organization (WHO) (2005) Summary Country Profile for HIV/AIDS Treatment Scale-Up - Ukraine. Geneva: World Health Organization.
34. World Health Organization (WHO) (2009) Global Price Reporting Mechanism. Geneva: World Health Organization.
35. Bruce RD, Dvoryak S, Sylla L, Altice FL (2007) HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine-programme description and policy implications. Int J Drug Policy 18: 326-328. (Pubitemid 47135596)
36. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, et al. (2007) Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment. Southampton, United Kingdom: National Institute for Health Research - Health Technology Assessment Programme.
37. International HIV/AIDS Alliance in Ukraine (2008) Methadone substitution therapy starts in Ukraine. Kyiv, Ukraine: International HIV/AIDS Alliance in Ukraine.
38. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT (2010) Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr 54: 548-555.
39. Golub SA, Operario D, Gorbach PM (2010) Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep 7: 201-209.
40. Myers GM, Mayer KH (2011) Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS 25: 63-71.
41. Juusola JL, Brandeau ML, Owens DK, Bendavid E (2012) The cost-effectiveness of preexposure prophylaxis for HIV prevention in men who have sex with men in the United States. Ann Intern Med 156: 541-550.
42. Gold MR, Siegel J, Russell L, Weinstein M (1996) Cost-Effectiveness in Health and Medicine. New York: Oxford University Press.
43. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance (2008) Epidemiological Factsheet on HIV and AIDS: Core Data on Epidemiology and Response - Ukraine. Geneva: World Health Organization (WHO) and Joint United Nations Programme on HIV/AIDS (UNAIDS).
44. Murray CJ, Lopez A (2002) World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization.
45. The World Bank (2013) GDP per capita, PPP (current international $). Washington, DC: World Bank.
46. Partnership for Supply Chain Management (2013) E-catalog: ARVs.
47. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, et al. (2013) The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med 10: e1001401.
48. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, et al. (2008) Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 22: 1829-1839.
49. Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, et al. (2012) The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study. PLoS Med 9: e1001323.
50. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, et al. (2009) HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clinical Infectious Diseases 48: 806-815.
51. Nichols BE, Boucher CA, van Dijk JH, Thuma PE, Nouwen JL, et al. (2013) Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study. PLoS One 8: e59549.
52. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, et al. (2013) The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS 27: 447-458.
53. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, et al. (2011) Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 8: e1001123.
54. Pretorius C, Stover J, Bollinger L, Bacaër N, Williams B (2010) Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One 5: e13646.
55. Barcal K, Schumacher J, Dumchev K, Moroz L (2005) A situational picture of HIV/AIDS and injection drug use in Vinnitsya, Ukraine. Harm Reduct J 2: 16.
56. Booth RE, Kwiatkowski CF, Brewster JT, Sinitsyna L, Dvoryak S (2006) Predictors of HIV sero-status among drug injectors at three Ukraine sites. AIDS 20: 2217-2223. (Pubitemid 44684713)
57. Booth RE, Kwiatkowski CF, Mikulich-Gilbertson SK, Brewster JT, Salomonsen-Sautel S, et al. (2006) Predictors of risky needle use following interventions with injection drug users in Ukraine. Drug Alcohol Depend 82: S49-S55. (Pubitemid 44183622)
58. Long EF, Stavert RR (2013) Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. J Gen Intern Med Epub ahead of print.
59. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, et al. (2012) The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clinical Infectious Diseases 54: 1504-1513.
60. Pinkerton SD, Abramson PR (1997) Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 44: 1303-1312. (Pubitemid 27186886)
61. Wolfe D, Carrieri MP, Shepard D (2010) Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 376: 355-366.
62. Dvoriak S (2007) Opioid Substitution Therapy (OST) with Buprenorphine in Ukraine - Way to Prevent HIV/AIDS among IDUs. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, Australia.